GLAXOSMITHKLINE PLC Form 6-K January 16, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 16 January 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

### GlaxoSmithKline plc (the 'Company')

#### Transaction notification

	<ul><li>Details of PDMR/person closely associa</li><li>Name</li></ul>	ted with then Ms E Walm	
	) Position/status	Chief Execu	•
	Initial notification/ amendment	Initial notifi	cation
2	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market parti	cipant, auction
b	Name  Details of the transaction(s): section to be instrument; (ii) each type of transaction; place where transaction(s) has been conditionally in the section of the section in the section is the section of the section in the secti	e repeated fo (iii) each dat	TVUYLO1D793 r (i) each type of
a	Description of the financial instrument		•
b	Nature of the transaction	paid to share January 201 Shares held	•
c	Price(s) and volume(s)	£13.306 £13.306 £13.306 £13.306 £13.306 £13.306	87.861 87.861 217.580 217.564 236.894 236.879
d	Aggregated information		
d)	Aggregated volume Price	1,084.639 £13.306	
e	Date of the transaction	2018-01-11	

f)	Place of the transaction	London Stoo (XLON)	ck Exchange
<ul><li>a)</li><li>b)</li></ul>	Details of PDMR/person closely associa Name Position/status Initial notification/	Mr R G Cor President, G	nnor dobal ing & Supply
,	amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction;	e market parti GlaxoSmith 5493000HZ e repeated fo	cipant, auction  Kline plc  TVUYLO1D793  r (i) each type of
a)	place where transaction(s) has been conc Description of the financial instrument		•
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.	
c)	Price(s) and volume(s)	Price(s) £13.306 £13.306 £13.306 £13.306	Volume(s) 64.344 64.344 147.828 123.348
d)	Aggregated information  Aggregated volume Price	523.198 £13.306	
e) f)	Date of the transaction Place of the transaction	2018-01-11 London Stoo (XLON)	ck Exchange

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

President, Global Vaccines b) Position/status

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary

Shares held in the Company's 2009 Deferred Annual Bonus

Plan.

Price(s) Volume(s)

£13.306 207.321

c) Price(s) and volume(s)

b) Nature of the transaction

£13.306 207.306

Aggregated information

d)

414.627 Aggregated volume Price

£13.306

e) Date of the transaction 2018-01-11

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr S Dingemans a) Name Chief Financial Officer b) Position/status

Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction 2.

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b) LEI

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

**Acquisition of Ordinary** 

place where	transaction	(c) has	haan	conducted
Diace where	t transaction	us) nas	neen	conducted

			Ordinary shares of 25 pence
a)	Description of the financial instrument	each ('Ordinary Shares')	
		ISIN: GB0009252882	

Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s) £13.306 122.724 £13.306 122.707 £13.306 287.332 £13.306 287.316

£13.306 215.211

£13.306 215.211

#### Aggregated information

c) Price(s) and volume(s)

d)
Aggregated volume Price
1,250.501
£13.306

e) Date of the transaction 2018-01-11

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics &

Compliance

c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	•	ares of 25 pence nary Shares') 009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £13.306 45.052	
		£13.306	45.052
	Price(s) and volume(s)	£13.306	106.239
c)		£13.306	106.239
		£13.306	77.966
		£13.306	77.951
d)	Aggregated information Aggregated volume Price	458.499 £13.306	
e)	Date of the transaction	2018-01-11	
f)	Place of the transaction	London Sto (XLON)	ck Exchange
1. a)	Details of PDMR/person closely associa Name	Mr B McNa	ımara
b)	Position/status	CEO, GSK Healthcare	Consumer
c)	Initial notification/ amendment	Initial notifi	cation
2.	Details of the issuer, emission allowance market participant, auction		
a)	platform, auctioneer or auction monitor Name	GlaxoSmith	Kline plc
b)	LEI  Details of the transaction(s): section to b		TVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		

a) Description of the financial instrument

American Depositary Shares

('ADSs')

ISIN: US37733W1053

Acquisition of ADSs

following the re-investment

of dividends paid to

b) Nature of the transaction shareholders on 11 January

> 2018 on ADSs held in the Company's 2009 Deferred

Annual Bonus Plan.

Price(s) Volume(s)

87.876 \$36.84 c) Price(s) and volume(s)

Aggregated information

d) Aggregated volume Price

87.876

\$36.84

e) Date of the transaction 2018-01-11

Place of the transaction New York Stock Exchange

(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

Initial notification/ Initial notification c)

amendment

b) Nature of the transaction

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11

January 2018 on Ordinary Shares held in the Company's

2009 Deferred Annual Bonus

Plan.

Price(s) Volume(s)

£13.306 72.194 £13.306 72.194 £13.306 135.207 £13.306 135.207 £13.306 98.121 £13.306 98.106

Aggregated information

d)

Aggregated volume Price 611.029 £13.306

e) Date of the transaction 2018-01-11

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

Initial notification/

c) Initial notification amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument

each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary

Shares held in the Company's 2009 Deferred Annual Bonus

Plan.

Price(s) Volume(s) £13.306 97.174

£13.306 97.158

b) Nature of the transaction

197.805

197.805

£13.306

£13.306

		£13.306	147.686
		£13.306	147.686
d)	Aggregated information	885.314	
	Aggregated volume Price	£13.306	
e)	Date of the transaction	2018-01-11	
f)	Place of the transaction		ck Exchange
1.	Details of PDMR/person closely associa		
	Position/status Initial notification/	Mr P C Thomson President, Global Affairs	
c)		Initial notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market parti	cipant, auction
	Name LEI	GlaxoSmith 5493000HZ	Kline plc TVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each dat	
	prace where transaction(s) has been cone	Ordinary sh	ares of 25 pence
a)	Description of the financial instrument		nary Shares') 09252882
		Acquisition	of Ordinary
		Shares follo re-investme	wing the nt of dividends
b)	Nature of the transaction	paid to shareholders on 11 January 2018 on Ordinary	
		Shares held in the Company's 2009 Deferred Annual Bonus Plan.	
		Price(s)	Volume(s)
		£13.306	66.002
c)	Price(s) and volume(s)	£13.306	121.024

£13.306 92.975

	Aggregated information		
d)	Aggregated volume Price	280.001 £13.306	
	Date of the transaction Place of the transaction	2018-01-11 London Stoo	ck Exchange
f)	The of the fransaction	(XLON)	on Englange
1. a)	Details of PDMR/person closely associa Name	ted with then Mr D E Tro	
b)	Position/status	SVP & Gen	eral Counsel
c)	Initial notification/ amendment	Initial notifi	cation
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmith	
b)	LEI		TVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
			epositary Shares
a)	Description of the financial instrument	('ADSs') ISIN: US37'	733W1053
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 January 2018 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.  Price(s) Volume(s)	
		\$36.84	50.006
		\$36.84	50.006
c)	Price(s) and volume(s)	\$36.84	112.593
<i>\( \)</i>		\$36.84	112.593
		\$36.84	93.253
		\$36.84	93.239

### Aggregated volume Price

		511.690	
		\$36.84	
e) f)	Date of the transaction Place of the transaction	2018-01-11 New York S (XNYS)	tock Exchange
1. a) b)	Details of PDMR/person closely associa Name Position/status	ted with them Dr P J T Val President, R	lance
c)	Initial notification/ amendment	Initial notific	cation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market parti	cipant, auction
a) b)	Name LEI		TVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary sha each ('Ordin ISIN: GB00	•
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £13.306 143.039	
		£13.306	143.039
٠,	Price(s) and volume(s)	£13.306	232.681
c)		£13.306	232.681
		£13.306	160.411

£13.306

160.411

d) Aggregated information

Aggregated volume Price

1,072.262 £13.306

e) Date of the transaction
Place of the transaction

2018-01-11

London Stock Exchange

(XLON)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: January 16, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc